The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Human pluripotent stem cell‐derived products: Advances towards robust, scalable and cost‐effective manufacturing strategies
Abstract
The ability to develop cost‐effective, scalable and robust bioprocesses for human pluripotent stem cells (hPSCs) will be key to their commercial success as cell therapies and tools for use in drug screening and disease modelling studies. This review outlines key process economic drivers for hPSCs and progress made on improving the economic and operational feasibility of hPSC bioprocesses. Factors influencing key cost metrics, namely capital investment and cost of goods, for hPSCs are discussed. Step efficiencies particularly for differentiation, media requirements and technology choice are amongst the key process economic drivers identified for hPSCs. Progress made to address these cost drivers in hPSC bioprocessing strategies is discussed. These include improving expansion and differentiation yields in planar and bioreactor technologies, the development of xeno‐free media and microcarrier coatings, identification of optimal bioprocess operating conditions to control cell fate and the development of directed differentiation protocols that reduce reliance on expensive morphogens such as growth factors and small molecules. These approaches offer methods to further optimise hPSC bioprocessing in terms of its commercial feasibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modern bioprocessing technology and protocols have developed to the point of producing functional, clinically relevant numbers of pluripotent stem cells for use as cell and tissue source material1–3.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931
A ROCK inhibitor permits survival of dissociated human embryonic stem cells
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J. B., Nishikawa, S., Nishikawa, S.-I., Muguruma, K., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1310 · Cited by 2,055
Self-formation of optic cups and storable stratified neural retina from human ESCs
Nakano, T., Ando, S., Takata, N., Kawada, M., Muguruma, K., Sekiguchi, K., Saito, K., Yonemura, S., Eiraku, M., & Sasai, Y. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.009 · Cited by 1,447
Idelson, M., Alper, R., Obolensky, A., Ben-Shushan, E., Hemo, I., Yachimovich-Cohen, N., Khaner, H., Smith, Y., Wiser, O., Gropp, M., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.07.002 · Cited by 486
Generation of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem Cells
Sullivan, G. J., Hay, D. C., Park, I.-H., Fletcher, J., Hannoun, Z., Payne, C. M., Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., et al. (2010) · Hepatology · doi:10.1002/hep.23335 · Cited by 445
Scalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells
Kehoe, D. E., Jing, D., Lock, L. T., & Tzanakakis, E. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0454 · Cited by 264 · cited 2×
“4 × 106 hPSCs/mL have been achieved using dynamic, aggregate-based culture techniques [76].”
BackgroundMethodBardy, J., Chen, A. K., Lim, Y. M., Wu, S., Wei, S., Weiping, H., Chan, K., Reuveny, S., & Oh, S. K. W. (2013) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2012.0146 · Cited by 111
Weng, Z., Kong, C.-W., Ren, L., Karakikes, I., Geng, L., He, J., Chow, M. Z. Y., Mok, C. F., Chan, H. Y. S., Webb, S. E., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0509 · Cited by 109
Fluri, D. A., Tonge, P. D., Song, H., Baptista, R. P., Shakiba, N., Shukla, S., Clarke, G., Nagy, A., & Zandstra, P. W. (2012) · Nature Methods · doi:10.1038/nmeth.1939 · Cited by 106
Research works printed but not linked: 97
- 10.1016/j.cell.2006.07.024 · DOI · Paper page
- 10.1016/j.cell.2007.11.019 · DOI · Paper page
- 10.1038/nature10761 · DOI · Paper page
- 10.1038/nrd3000 · DOI · Paper page
- Grskovic M., 2011, Induced pluripotent stem cells –Opportunities for disease modelling and drug discovery., Nat. Rev. Drug Discov., 10, 915, 10.1038/nrd3577 · DOI · Paper page
- 10.1172/JCI40553 · DOI · Paper page
- 10.1038/ncb0511-497 · DOI · Paper page
- 10.1016/j.pharmthera.2012.01.005 · DOI
- 10.1002/bies.201200053 · DOI
- 10.1016/j.stem.2010.05.012 · DOI
- 10.2217/rme.12.40 · DOI
- 10.1089/scd.2012.0202 · DOI
- 10.1016/S0140-6736(12)60028-2 · DOI · Paper page
- 10.1371/journal.pone.0037004 · DOI · Paper page
- 10.1098/rsif.2008.0442 · DOI · Paper page
- 10.2217/17460751.4.2.153 · DOI
- 10.1002/bit.25008 · DOI · Paper page
- 10.1038/ncb2894 · DOI · Paper page
- 10.2217/rme.11.101 · DOI
- 10.1038/nrd2403 · DOI
- 10.1002/btpr.1825 · DOI
- 10.1016/j.tibtech.2012.03.003 · DOI · Paper page
- 10.1016/j.biotechadv.2013.08.009 · DOI
- 10.1016/j.biotechadv.2013.03.006 · DOI · Paper page
- 10.1002/stem.1260 · DOI · Paper page
- 10.1007/s10616-013-9687-7 · DOI
- 10.1089/ten.teb.2009.0270 · DOI · Paper page
- Lang H. J., 1948, Simplified approach to preliminary cost estimates., Chem. Eng., 55, 112
- 10.1002/bit.24608 · DOI · Paper page
- 10.1016/j.cherd.2013.08.021 · DOI
- 10.1002/bit.21673 · DOI
- 10.1021/bp049692b · DOI
- 10.1002/bit.20757 · DOI
- 10.1387/ijdb.082590le · DOI
- Rowley J., 2012, Meeting lot‐size challenges of manufacturing adherent cells for therapy., BioProcess Int., 10, 16
- 10.1016/j.biotechadv.2011.06.009 · DOI · Paper page
- Brandenburger R., 2011, Cell therapy bioprocessing., BioProcess Int., 9, 30
- 10.1002/bit.22187 · DOI · Paper page
- 10.1016/j.scr.2009.02.005 · DOI · Paper page
- 10.1002/bit.20045 · DOI · Paper page
- 10.1089/ten.tec.2011.0717 · DOI · Paper page
- 10.1080/20013891081692 · DOI · Paper page
- 10.1089/ten.tec.2010.0320 · DOI
- 10.1038/nmeth.1593 · DOI · Paper page
- 10.1016/j.scr.2013.07.011 · DOI
- 10.1089/ten.tec.2012.0141 · DOI
- 10.1016/j.jbiotec.2008.07.1997 · DOI · Paper page
- 10.1590/S0100-879X2009000600007 · DOI
- 10.1016/j.jbiotec.2010.06.015 · DOI
- 10.1089/ten.tec.2013.0191 · DOI
- 10.1038/nbt.1620 · DOI · Paper page
- 10.1016/j.scr.2011.04.007 · DOI · Paper page
- 10.1038/nbt.1629 · DOI · Paper page
- 10.1038/nbt.1631 · DOI · Paper page
- 10.1089/ten.tea.2013.0523 · DOI
- 10.1016/j.biomaterials.2012.01.060 · DOI
- 10.1089/ten.tec.2009.0228 · DOI · Paper page
- 10.1002/bit.24375 · DOI
- 10.1089/ten.tec.2012.0161 · DOI
- 10.1016/j.scr.2012.02.001 · DOI
- 10.1038/nprot.2011.318 · DOI · Paper page
- 10.1038/nprot.2011.325 · DOI
- 10.1016/j.scr.2010.03.005 · DOI · Paper page
- 10.1016/j.scr.2010.03.001 · DOI · Paper page
- 10.1089/ten.tea.2008.0455 · DOI · Paper page
- 10.1186/scrt136 · DOI
- 10.1007/s12265-012-9423-2 · DOI
- 10.1002/stem.31 · DOI · Paper page
- 10.1161/CIRCRESAHA.108.192237 · DOI · Paper page
- 10.1007/s12015-010-9189-3 · DOI
- 10.3389/fphys.2012.00047 · DOI
- 10.1002/stem.1166 · DOI
- 10.1146/annurev-bioeng-071910-124715 · DOI
- 10.1002/stem.768 · DOI
- 10.1371/journal.pone.0018293 · DOI · Paper page
- 10.1038/nbt.2249 · DOI · Paper page
- 10.1016/j.jcyt.2013.03.006 · DOI
- Diekmann U. Lenzen S. Naujok O. A reliable and efficient protocol for human pluripotent stem cell differentiation into the definitive endoderm based on dispersed single cells.Stem Cells Dev.2014 DOI:10.1089/scd.2014.0143. · DOI
- 10.1002/stem.1622 · DOI
- 10.2217/rme.13.36 · DOI
- 10.1089/ten.tec.2010.0104 · DOI
- 10.1089/scd.2013.0088 · DOI
- 10.1089/ten.tea.2010.0235 · doi:10.1089/ten.tea.2010.0235
- 10.1089/ten.tea.2007.0247 · DOI
- 10.1016/j.biomaterials.2013.05.079 · DOI
- 10.1039/c2ib20040f · DOI
- 10.1002/bit.24782 · DOI
- 10.1089/ten.tea.2010.0014 · DOI
- 10.1038/nature08073 · DOI · Paper page
- 10.1089/scd.2011.0225 · DOI
- 10.1016/j.ymeth.2008.10.015 · DOI
- 10.1016/j.tibtech.2010.03.002 · DOI · Paper page
- 10.1016/j.mvr.2011.06.013 · DOI
- 10.1371/journal.pone.0052246 · DOI
- 10.1002/biot.201300245 · DOI
- 10.1002/bit.24717 · DOI
- 10.1002/glia.20127 · DOI · Paper page
Cited by
Progress and challenges in large-scale expansion of human pluripotent stem cells
Kropp, C., Massai, D., & Zweigerdt, R. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.032 · Cited by 167
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00183-7 · Cited by 33
Metadata
- Authors
- Jenkins, M. J., & Farid, S. S.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2014-11-19
- Volume
- 10
- Issue
- 1
- Pages
- 83-95
- ISSN
- 1860-6768
- 1860-7314
- Cited by
- 95
- References
- 10
- Language
- en
- Funders
- Engineering and Physical Sciences Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.